These findings suggest that therapeutic targeting of IRF5 or its upstream regulators may require sex-specific strategies to achieve optimal outcomes in metabolic disease The sex-specific associations we report have important therapeutic implications. This evidence concerns the gene IRF5 and metabolic disease.